Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

Diabetic Medicine

Volumn 19, Issue 2, 2002, Pages 119-124

  Serrano Rios, M ^a   Melchionda, N ^b   Moreno Carretero, E ^c  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Laboratorios Knoll SA   (Spain)

Author keywords

Obesity; Sibutramine; SNRI; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PLACEBO; SIBUTRAMINE; SULFONYLUREA;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ANXIETY; ARTHRALGIA; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; BODY SIZE; BODY WEIGHT; CALORIC RESTRICTION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC OBESITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VERTIGO; WEIGHT REDUCTION; XEROSTOMIA;

APPETITE DEPRESSANTS; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CYCLOBUTANES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; PLACEBOS; SULFONYLUREA COMPOUNDS; TRIGLYCERIDES; WEIGHT LOSS;

EID: 0036124103     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00655.x     Document Type: Article

References (25)

1. UK prospective diabetes study IV. Characteristics of newly presenting type 2 diabetic patients: Male preponderance and obesity at different ages
2. Weight and non-insulin-dependent diabetes mellitus
3. Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome
4. Abdominal obesity an important component of insulin-resistance syndrome
5. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease
6. Pathophysiology of insulin resistance in human disease
7. Management of the obese diabetic patient
8. Weight control. Metabolic and cardiovascular effects
9. Sibutramine. A review of its contribution to the management of obesity
10. Long-term maintenance of weight loss after a very-low-calorie diet: A randomised blinded trial of efficacy and tolerability of sibutramine
11. Sibutramine - A review of clinical efficacy
12. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females
13. Effects of sibutramine versus placebo in NIDDM
14. Intensive blood-glucose control with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
15. A suggestion for using powerful and informative tests of normality
16. Cardiovascular risk in type 2 diabetes
17. A desktop guide to type 2 diabetes mellitus
18. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)
19. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
20. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
21. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomised double-blind study
22. Anorectic agents in non-insulin dependent diabetes mellitus
23. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study
24. Absence of cardiac valve dysfunction in obese patients treated with sibutramine